Immunology and Immunotherapy
"Our team has developed very promising immunoregulatory molecules and vaccination strategies that are being evaluated in clinical trials."
DR. JUAN JOSÉ LASARTE RESEARCHER. IMMUNOLOGY AND IMMUNOTHERAPY RESEARCH PROGRAM
Modulation of the immune system is revolutionizing the fight against cancer and infectious diseases. Recent advances show that an individual's immune system can be activated to eliminate tumor cells and extend patients' lives.
The Immunology and Immunotherapy Program at Cima focuses on the translational development of new therapeutic tools for the treatment of different types of cancers and infectious diseases.
We have facilities for the production of therapeutic grade cells and the development and production of gene therapy vectors that allow us to optimize strategies that are in the clinical development phase, and to generate new immunotherapy alternatives for patients.
We have long experience in the development of novel vaccines that have led to patents and the creation of biotechnology companies.
Our innovative work in the development of immunomodulation strategies with the generation of very promising immunomodulatory molecules has also been the subject of patents and collaboration contracts with pharmaceutical companies.
We collaborate with pharmaceutical companies in the design and development of immunotherapy clinical trials in cancer patients.
Our team is formed by nationally and internationally recognized researchers and immunologists from the Clínica Universidad de Navarra.
Need more information?
If you are interested in learning more about our research, please contact us.
Objectives of the Research Program in Immunology and Immunotherapy
Development of molecules and immunomodulation strategies
Identify and generate molecules with immunotherapeutic potential and develop immunomodulation strategies.
Development of therapeutic vaccines against different types of cancer, infectious diseases and other pathologies.
Adoptive cell therapy
Design and evaluate adoptive cell therapy strategies for the treatment of oncologic diseases.
First Spanish immunotherapy
Cima and the Clínica Universidad de Navarra have coordinated a study that has managed to stabilize and improve the evolution in a group of patients with melanoma, lung cancer and renal cancer by combining the BO-112 molecule and two anti PD-1 antibodies (nivolumab or pembrolizumab).
The BO-112 formulation is based on double-stranded RNA molecules and achieves a direct antitumor response that is in turn enhanced by activation of innate immunity mechanisms. This immunotherapy treatment is injected directly into the tumor or its metastases.
Our research groups
We seek to improve therapeutic alternatives against cancer by activating and boosting the immune system
Identification of small molecules that block Treg cell activity to develop antitumor therapies.
Combination Strategies for
Study of immunomodulatory molecular mechanisms and their exploitation in cancer immunotherapy.
Identification of new targets to enhance the immune response against cancer.
Adoptive Cell Therapy
Strategies to improve the efficacy of adoptive cell transfer of tumor-infiltrating T lymphocytes (TILs).
Vaccination based on dendritic cell modulation.
FROM THE LABORATORY TO THE PATIENT
Cutting-edge translational research
Our program is transversal and supports other Cima programs to promote, together with the clinical departments of the Clínica Universidad de Navarra, the development of specific reagents for immunomonitoring and the design of immunotherapies for different diseases, which can be applied in clinical activity.
We develop vaccines based on dendritic cells increasing their immunotherapeutic effect.
Relationships with companies
Our research has resulted in patents and several collaborations with national and international pharmaceutical companies.
Participation in clinical trials
We collaborate with industry in the development of clinical trials and promote our own clinical trials in collaboration with the Cell Therapy Area of the Clínica Universidad de Navarra.
Would you like to help us?
Thanks to the generosity of many people, the Cima Universidad de Navarra is a reality that strives to offer therapeutic solutions to achieve personalized medicine for patients.
Meet the research team
Scientific activity of the
Research Program in Immunology and Immunotherapy
Latest scientific publications
- Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB 1 and CB 2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia Jan 12, 2022 | Magazine: Science Translational Medicine
- CD137 (4-1BB) costimulation of CD8 + T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation Dec 15, 2021 | Magazine: Nature Communications
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies May 18, 2021 | Magazine: Nature Reviews. Clinical Oncology
- Advances in immunotherapy for hepatocellular carcinoma Apr 13, 2021 | Magazine: Nature Reviews. Gastroenterology & Hepatology